Table 1.
Baseline characteristics before and after matching RESORCE population to CELESTIAL population with ≥3 months of prior sorafenib duration
| RESORCE |
CELESTIAL |
|||||
|---|---|---|---|---|---|---|
| regorafenib (N = 320) | regorafenib matched (ESS = 214) | placebo (N = 167) | placebo matched (ESS = 82) | cabozantinib (N = 241) | placebo (N = 117) | |
| ECOG status = 1, % | 33.4 | 44.4 | 30.5 | 42.7 | 44.4 | 42.7 |
| Geographic region = Asia, % | 34.7 | 20.3 | 37.7 | 17.9 | 20.3 | 17.9 |
| Prior sorafenib duration ≥6 months, % | 72.2 | 59.3 | 73.7 | 63.2 | 59.3 | 63.2 |
| Age, years | ||||||
| Median [range] | 64.0 [19–85] | 65.0 [19–85] | 62.0 [23–83] | 65.0 [23–83] | 65.0 [28–86]a | 67.5 [36–86]a |
| Male, % | 90.0 | 79.7 | 89.2 | 89.7 | 79.7 | 89.7 |
| Extrahepatic spread, % | 69.7 | 75.9 | 76.0 | 75.2 | 75.9 | 75.2 |
| Macrovascular invasion, % | 27.2 | 21.6 | 26.9 | 34.2 | 21.6 | 34.2 |
| Hepatitis B, % | 36.9 | 32.8 | 36.5 | 34.2 | 32.8 | 34.2 |
| Hepatitis C, % | 21.6 | 27.0 | 22.2 | 29.9 | 27.0 | 29.9 |
| Alcohol use, % | 25.3 | 24.5 | 29.9 | 13.7 | 24.5 | 13.7 |
| AFP ≥400 ng/mL, % | 41.6 | 38.2 | 43.7 | 38.5 | 38.2 | 38.5 |
| Child-Pugh class A, % | 98.1 | 97.5 | 97.0 | 95.8 | 98.8b | 98.8b |
Bold numbers indicate matched characteristics. AFP, alpha-fetoprotein; ECOG, Eastern Cooperative Oncology Group; ESS, effective sample size.
a
Reported in ref. [17] only for population who received sorafenib ≥6 months prior to screening.
b
Reported in ref. [16] only for the overall CELESTIAL population.